Role of the bone marrow microenvironment in tumor transformation of plasma cell dyscrasias
https://doi.org/10.51523/2708-6011.2021-18-1-2
Abstract
Despite significant progress in the understanding of the pathogenesis of paraproteinemic hemoblastoses, these diseases remain incurable. In their development, they go through the stage of paraproteinemias, benign diseases, characterized by the detection of monoclonal paraprotein in the blood serum and / or urine, presence of clonal plasma cells in the bone marrow or in extramedullary tissues. It remains unclear why some paraproteinemias progress to multiple myeloma or other lymphoid tumors and how malignant progression occurs. An important role in the progression is played by molecular and genetic mechanisms, cytokines. Nevertheless, little is known about how the bone marrow microenvironment influences disease progression. In this review, we made an attempt to summarize the most significant biological, clinical characteristics on the course of paraproteinemias and the role of changes in the bone marrow microenvironment that contribute to malignant transformation.
About the Authors
Zh. Kozich
Republican Research Center for Radiation Medicine and Human Ecology
Belarus
Belarus
Zhanna M. Kozich, Cand.Sc. (Medicine), hematologist at the Hematology Department for Adults, Gomel
L. A. Smirnova
Belarusian Medical Academy for Postgraduate Education
Belarus
Belarus
Ludmila A. Smirnova, D.Sc. (Medicine), Professor, Head of the Department of Hematology and Transfusiology, Minsk
V. N. Martinkov
Republican Research Center for Radiation Medicine and Human Ecology
Belarus
Belarus
Victor N. Martinkov, Cand.Sc. (Biology), Associate Professor, senior researcher at the Laboratory of Molecular Genetics, Gomel
References
1. Morelli E, Gullà A, Rocca R, Federico C, Raimondi L, Malvestiti S et al. The Non-Coding RNA Landscape of Plasma Cell Dyscrasias. Cancers (Basel). 2020;12(2):320. https://doi.org/10.3390/cancers12020320
2. Rajkumar SV. Multiple myeloma: 2018 update on diagnosis, risk-stratification, and management. Am J Hematol. 2018;93(8):1091–110. https://doi.org/10.1002/ajh.25117
3. Manier S, Sacco A, Leleu X, Ghobrial IM, Roccaro AM. Bone Marrow Microenvironment in Multiple Myeloma Progression. J Biomed Biotechnol. 2012;2012:1–5. https://doi.org/10.1155/2012/157496
4. Goubran HA, Kotb RR, Stakiw J, Emara ME, Burnouf T. Regulation of Tumor Growth and Metastasis: The Role of Tumor Microenvironment. Cancer Growth Metastasis. 2014;7:9–18. https://doi.org/10.4137/CGM.S11285
5. Makoni SN, Laber DA. Clinical spectrum of myelophthisis in cancer patients. Am J Hematol. 2004;76(1):92–93. https://doi.org/10.1002/ajh.20046
6. Maes K, Nemeth E, Roodman GD, Huston A, Esteve F, Freytes C et al. In anemia of multiple myeloma, hepcidin is induced by increased bone morphogenetic protein 2. Blood. 2010;116(18):3635–44. https://doi.org/10.1182/blood-2010-03-274571
7. Xi H, An R, Li L, Wang G, Tao Y, Gao L. Myeloma bone disease: Progress in pathogenesis. Prog Biophys Mol Biol. 2016;122(2):149–55. https://doi.org/10.1016/j.pbiomolbio.2016.08.003
8. Vacca A. Endothelial cells in the bone marrow of patients with multiple myeloma. Blood. 2003;102(9):3340–8. https://doi.org/10.1182/blood-2003-04-1338
9. Kyle RA, Larson DR, Therneau TM, Dispenzieri A, Kumar S, Cerhan JR, et al. Long-Term Follow-up of Monoclonal Gammopathy of Undetermined Significance. N Engl J Med. 2018;378(3):241–49. https://doi.org/10.1056/NEJMoa1709974
10. Lawson MA, McDonald MM, Kovacic N, Hua Khoo W, Terry RL, Down J et al. Osteoclasts control reactivation of dormant myeloma cells by remodelling the endosteal niche. Nat Commun. 2015;6(1):8983. https://doi.org/10.1038/ncomms9983
11. Mansour A, Wakkach A, Blin-Wakkach C. Emerging roles of osteoclasts in the modulation of bone microenvironment and immune suppression in multiple myeloma. Front Immunol. 2017;8:954. https://doi.org/10.3389/fimmu.2017.00954
12. Kristinsson SY, Tang M, Pfeiffer RM, Björkholm M, Blimark C, Mellqvist U-H et al. Monoclonal gammopathy of undetermined significance and risk of skeletal fractures: a population-based study. Blood. 2010;116(15):2651–55. https://doi.org/10.1182/blood-2010-04-282848
13. Gundesen MT, Lund T, Moeller HEH, Abildgaard N. Plasma Cell Leukemia: Definition, Presentation, and Treatment. Curr Oncol Rep. 2019;21(1):8. https://doi.org/10.1007/s11912-019-0754-x
14. Swerdlow S, Campo E, Harris N, Jaffe E, Pileri S, Stein H et al., editors. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, revised 4th edition. WHO Classif tumours. 4th ed. Lyon, France: IARC; WHO; 2008 [cited 2020 Oct 5]. Available from: https://publications.iarc.fr/Book-And-Report-Series/Who-Classification-Of-Tumours/WHO-Classification-Of-Tumours-Of-Haematopoietic-And-Lymphoid-Tissues-2017
15. Joseph NS, Gentili S, Kaufman JL, Lonial S, Nooka AK. High-risk Multiple Myeloma: Definition and Management. Clin Lymphoma Myeloma Leuk. 2017;17:S80–7. https://doi.org/10.1016/j.clml.2017.02.018
16. Vaxman I, Dispenzieri A, Muchtar E, Gertz M. New developments in diagnosis, risk assessment and management in systemic amyloidosis. Blood Rev. 2020;40:100636. https://doi.org/10.1016/j.blre.2019.100636
17. Merlini G, Comenzo RL, Seldin DC, Wechalekar A, Gertz MA. Immunoglobulin light chain amyloidosis. Expert Rev Hematol. 2014;7(1):143–56. https://doi.org/10.1586/17474086.2014.858594
18. Miralles GD, O’Fallon JR, Talley NJ. Plasma- Cell Dyscrasia with Polyneuropathy. N Engl J Med. 1992;327(27):1919–23. https://doi.org/10.1056/NEJM199212313272705
19. Dispenzieri A, Kyle RA, Lacy MQ, Rajkumar SV, Therneau TM, Larson DR, et al. POEMS syndrome: definitions and long-term outcome. Blood. 2003;101(7):2496–506. https://doi.org/10.1182/blood-2002-07-2299
20. Dao LN, Hanson CA, Dispenzieri A, Morice WG, Kurtin PJ, Hoyer JD. Bone marrow histopathology in POEMS syndrome: a distinctive combination of plasma cell, lymphoid, and myeloid findings in 87 patients. Blood. 2011;117(24):6438–44. https://doi.org/10.1182/blood-2010-11-316935
Review
For citations:
Kozich Zh., Smirnova L.A., Martinkov V.N. Role of the bone marrow microenvironment in tumor transformation of plasma cell dyscrasias. Health and Ecology Issues. 2021;18(1):14-19. https://doi.org/10.51523/2708-6011.2021-18-1-2
Views: 525
Email this article 